gastrointestinal stromal tumors/únava

Odkaz je uložen do schránky

Vyberte typ řazení

Strana 1 z 70 Výsledek

Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of gastrointestinal stromal tumor (GIST) in 2000 was the start of a new era of targeted treatment. Since then, the median survival of patients with GIST has substantially increased. Prolonged survival and chronic TKI

[A case of multiple liver metastases after resection of gastrointestinal stromal tumor of the small intestine that was successfully treated with imatinib mesylate].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

A 73-year-old man was found to have an intestinal tumor, approximately 10 cm in diameter, on computed tomography (CT). In September 2001, he underwent partial resection of the jejunum with partial colectomy and left nephrectomy. Pathological examination showed 2 mitoses per 50 high-power fields, and

A rare case of extraluminal gastrointestinal stromal tumor of the ileum presenting with lower urinary tract symptoms: A case report.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Benign prostatic hyperplasia, bladder outlet obstruction, and overactive bladder are major causes of lower urinary tract symptoms (LUTS). Tumor compression of the urinary bladder resulting in LUTS was clinically observed. Gastrointestinal stromal tumors (GISTs) presenting with LUTS

[A Case of Intraductal Growth Pattern Gastrointestinal Stromal Tumor of the Stomach That Was Difficult to Diagnose by Biopsy].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

The patient, a 76-year-old man, presented to his local doctor's clinic with complaints of fatigue and lightheadedness. Because blood test results indicated anemia, he was referred to our hospital. Upper gastrointestinal endoscopy indicated a type 2 tumor of approximately 5 cm at the top of the

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib in patients with advanced imatinib-resistant gastrointestinal stromal tumors. METHODS A phase I intercohort dose-escalation trial

Expression of c-KIT oncoprotein in gastrointestinal stromal tumors in adults and children: guideline for diagnosis and treatment.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Gastrointestinal stromal tumors (GISTs) represent a distinct oncogenetic entity that is now center stage in clinical trials of kinase-targeted therapies. These neoplasms express the c-KIT oncoprotein and occur predominantly in adults, more rarely in children. Two selected cases of GIST expressing

[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To evaluate the efficacy and safety of imatinib mesylate in the treatment of patients as preoperative supplement, or used alone for unresectable and(or) metastatic gastrointestinal stromal tumor (GIST). METHODS A total of 30 cases with advanced GIST were proved pathologically. Among them,

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

CONCLUSIONS Despite having significant rationale, S0502 failed to accrue for a number of reasons.Vetting a trial first, with scientific experts and funding agencies, does not guarantee success, especially when dealing with a rare tumor and/or one with an existing highly effective therapy.In the

[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To evaluate the efficacy and safety of imatinib mesylate in the treatment of patients as preoperative supplement, or used alone for unresectable and/or metastatic gastrointestinal stromal tumors (GIST). METHODS A total of 51 cases with advanced GIST were proved pathologically. Among them,

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of gastrointestinal stromal tumors (GIST) although most patients develop resistance to first and second-line therapies. Regorafenib, an oral multi-targeted TKI, has demonstrated benefit in previously treated GIST

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs). METHODS The study was confined to adult patients with radiographically measurable GISTs. ET-743 was administered as a 24-hour

Immunohistochemical and molecular genetic analyses of multiple sporadic gastrointestinal stromal tumors.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

A 77-year-old Japanese male patient was admitted to our hospital complaining of general fatigue and melena. A gastroduodenal endoscopic examination revealed no definitive localized lesions. However, both a large amount of cruor and blood flow from the small intestine into the ascending colon was

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

BACKGROUND The authors conducted a two-arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in patients with

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

OBJECTIVE Motesanib (AMG 706) is a multitargeted anticancer agent with an inhibitory action on the human vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and the cellular stem-cell factor receptor (KIT). The aim of this single-arm phase II clinical study was

Internet-Delivered Cognitive Behavioral Therapy and Psychoeducation Program for Patients with Gastrointestinal Stromal Tumors

Články mohou překládat pouze registrovaní uživatelé

Přihlášení Registrace

Gastrointestinal stromal tumors (GIST) account for 0.2-3% of all cancer diagnoses and are thus considered a rare type of cancer. Severe levels of fatigue occur in 33% of patients on imatinib, but besides treatment, fatigue is also associated with psychological distress. As far as we know, only one

Předchozí
1
2
3
4
5
další

Připojte se k naší
facebookové stránce

Herbal & Natural Medicine

Nejúplnější databáze léčivých bylin podložená vědou

Funguje v 55 jazycích
Bylinné léky podporované vědou
Rozpoznávání bylin podle obrázku
Interaktivní mapa GPS - označte byliny na místě (již brzy)
Přečtěte si vědecké publikace související s vaším hledáním
Hledejte léčivé byliny podle jejich účinků
Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu